ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation

• Status: Completed
• Trial end date: 2021-02-28
• Target enrollment: 0
• Participant gender: All

Summary

Our study will compare all kidney transplant recipients receiving valganciclovir vs. valacyclovir for one year following kidney transplant and compare:

1. the incidence, magnitude and duration of CMV and EBV viremia in the first year after transplant.

2. the side effects of the anti-viral drugs requiring dose reduction or cessation

In addition, we will test renal tissue obtained from any biopsies post-transplant (surveillance or clinically indicated biopsies) by both polymerase chain reaction (PCR) and fluorescence in situ hybridization to assess for latent CMV and/or EBV.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Minnesota; University of Minnesota - Clinical and Translational Science Institute
• Treatments: Acyclovir; Ganciclovir; Valacyclovir; Valganciclovir

Criteria

Inclusion Criteria:

• All consenting kidney transplant recipients.

Exclusion Criteria:

• Non-consent.

• Recipients with allergies to valacyclovir or valganciclovir

• Recipients that are unable to independently understand the consent form and do not have a legally authorized representative.